Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib
2012-000425-45Phase 4Active
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sunitinib in renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) and islet cell tumor (2 arms). Primary endpoint: Primary: Differences in sunitinib pharmacokinetics between morning and evening dosing. Started Mar 2012; status: active.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)islet cell tumor
Beyond the preview
Go deeper on 2012-000425-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000425-45.